BBIO - BioMarin a market perform at Raymond James due to growth concerns
2023-09-28 11:07:29 ET
More on BioMarin Pharmaceutical
- BioMarin: Q2 2023 Confirmed My Bullish View
- BioMarin: More Growth Is Coming
- BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
- Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical
For further details see:
BioMarin a market perform at Raymond James due to growth concerns